Suppr超能文献

在 SARS-CoV-2 未感染和康复的医护人员中,体液免疫和细胞免疫应答的诱导动力学存在差异。

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers.

机构信息

Department of Medical Microbiology and Immunology, Diakonessenhuis, Utrecht, 3582 KE, The Netherlands.

Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

出版信息

Pathog Dis. 2022 Oct 3;80(1). doi: 10.1093/femspd/ftac035.

Abstract

Effective vaccination is a key element in the exit strategy from the current severe acute respiratory syndrome-CoV coronavirus-2 (SARS-CoV-2) pandemic, and may also offer protection against severe disease from future variants of concern. Here, we prospectively monitored T-cell responses over time, using ELISpot interferon-γ (INF-y) release assays, and B-cell responses, using serological tests, after vaccination and booster with BioNTech/Pfizer mRNA (Pfizer) and Janssen vector (Janssen/Johnson & Johnson) vaccines in hospital health care workers. Vaccine recipients were divided into seropositive and seronegative individuals at baseline, in order to determine the effect of natural immunity on vaccine-induced immune kinetics. We found that convalescent individuals mounted higher spike-specific INF-y-secreting T-cell responses and B-cell-mediated IgG responses, after receiving the Janssen vaccine or the first dose of the Pfizer vaccine. IgG levels corresponded to the virus neutralization capacity as measured by VNT assay. At 8 months postvaccination, spike-specific cellular immunity waned to low levels in individuals with or without prior natural immunity, whereas waning of humoral immunity occurred predominantly in naive individuals. The booster shot effectively reinduced both cellular and humoral immune responses. To conclude, our data supports the implemented single-dose mRNA booster strategy employed in the Netherlands. Furthermore, the level of pre-existing natural immunity may be factored into determining the optimal time window between future booster vaccines.

摘要

有效的疫苗接种是摆脱当前严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)大流行的关键策略,并且可能对未来令人关注的变异体引起的严重疾病提供保护。在这里,我们使用酶联免疫斑点干扰素-γ(INF-γ)释放检测,前瞻性监测了疫苗接种和加强针(BioNTech/Pfizer mRNA[辉瑞]和 Janssen 载体[强生/杨森])接种后,医院医护人员的 T 细胞反应随时间的变化,并使用血清学检测监测 B 细胞反应。疫苗接种者在基线时根据血清学结果分为血清阳性和血清阴性个体,以确定自然免疫对疫苗诱导免疫动力学的影响。我们发现,与接受辉瑞疫苗第一剂相比,恢复期个体在接受 Janssen 疫苗或辉瑞疫苗后,会产生更高的刺突特异性 INF-γ 分泌 T 细胞反应和 B 细胞介导的 IgG 反应。IgG 水平与病毒中和能力相对应,通过 VNT 检测进行测量。在接种疫苗后 8 个月,无论是否存在先前的自然免疫,个体的刺突特异性细胞免疫均减弱至低水平,而体液免疫的减弱主要发生在无经验个体中。加强针有效地重新诱导了细胞和体液免疫反应。总之,我们的数据支持了在荷兰实施的单剂 mRNA 加强针策略。此外,先前存在的自然免疫水平可能会影响未来加强疫苗接种的最佳时间窗口。

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验